Do like the potential here. FDA catalyst soon, potential approval for fluticare. Expanding revs and looking good into 2017. No R/S for uplisting and no immediate hurry to uplist. CEO Dr. Damaj says they want $3 for uplisting, if things progress well they won't need to RS, if they do by then it would be minimal. His track record says they won't need it.